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Abstract
Objective: Respiratory fluoroquinolones (RFQs) are widely used in the 
treatment of community-acquired pneumonia (CAP) in our region. Our 
aim was to find if there was outcome difference between RFQ-based 
versus RFQ-exempt regimens. 
Methods: A retrospective study of RFQs versus other used antimicro-
bial therapy (OUAT) in the treatment of patients with mid-to-moderate 
CAP adjusted by pneumonia severity score (PSI). Rates of treatment 
outcome at end-of- therapy i.e. clinical improvement, length of hospi-
tal stay and speed of recovery were evaluated. Patients were included 
if they had Mild-to-Moderate severity CAP, ≥18 years old, completed 
≥ 3 days of antimicrobials.
Results: 320 patients were included, mean age for all groups was 
49.63 years (P = 0.204), males 60.3 % (P = 0.219). All had similar PSI 
score (Pearson X2 test = 13.75, P = 0.185). The first group (24.4%) is 
composed of RFQs monotherapy. The second group (50.6%) is com-
posed of RFQs plus ß-lactams. The third group (25%) is composed of 
OUAT. Diabetes was the most common comorbidity among all (P = 
0.847). There was no significant difference among the three groups 
in clinical improvement (P = 0.424) and speed of recovery (P = 0.398), 
however length of hospital stay was significantly shorter for the RFQs 
monotherapy (P = 0.004).
Cumulative curve for probability of discharge did not show significant 
difference among the three therapy groups (P ≥ 0.20)
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Introduction
Community-acquired pneumonia is one of the most 
common infections afflicting individuals, each year 
about four millions are diagnosed with CAP in USA, 
one-quarter are hospitalized with considerable mor-
bidity and mortality. It is arbitrarily classified into 
mild, moderate and severe, whether for outpatient 
therapy, in-hospital, or ICU. Severity is classified 
based on either CURB 65 (confusion, uremia, respi-
ratory rate, low blood pressure, age ≥ 65 years) or 
pneumonia severity index (PSI) which is more so-
phisticated but a more accurate tool. CAP incidence 
ranges between 12 cases per 1,000 population 
–year to as high as 18.2, 27.9, 52.3 case per 1000 
population-year in individuals aged 65 - 69, 75 – 79 
and ≥ 85 years respectively [1, 2, 3, 4].
Due to these inevitabilities, caring for adult patients 
with CAP has been the focus of many guidelines 
such as the Infectious Diseases Society of America/
American Thoracic Society (IDSA/ATS) and the Brit-
ish Thoracic Society (BTS) among other societies. 
Studies addressing the outcome difference among 
various classes of antimicrobial agents prescribed 
in the treatment of CAP were conducted where 
quinolones were found superior to the comparator 
antimicrobials. In a meta-analysis comparing differ-
ent quinolones including levofloxacin, gemifloxacin 
and moxifloxacin, quinolones’ treated patients were 
found to have better clinical and microbiological re-
sponse compared to macrolides and ß-lactams, in 
addition, they were found more effective in severe 
pneumonia, those in need of hospitalization and 
parenteral therapy [5]. Furthermore, some studies 
compared the treatment outcome among quino-
lones; Olivier Leroy et al. compared ofloxacin or cip-
rofloxacin plus ß-lactam with a newer quinolone i.e. 
levofloxacin plus a ß-lactam. They concluded that 
levofloxacin is associated with lower mortality than 
ofloxacin or ciprofloxacin in severe pneumococcal 
CAP [6]. However, the British thoracic society guide-
lines statement; quinolones were found not supe-
rior to ß-lactams, macrolides in combination with 
ß-lactams and ß-lactam ß-lactamase inhibitors in 
the treatment of patients with mild-to-moderate 
severity CAP, also due to their higher cost and as-
sociation with methicillin resistant staphylococcus 
aureus (MRSA) and Clostridium difficile infection 
(CDI) they are not preferred as first line agents [7].
In our study, we examine if there are differences 
among using RFQ monotherapy versus combina-
tion, and other antimicrobial regimens not contain-
ing RFQs in patients with Mild-to-Moderate CAP 
requiring admission to a hospital ward. The primary 
outcome measures were clinical response at end of 
therapy and speed of recovery. Secondary outcome 
measures were mortality by 30 days and length of 
hospital stay.
Conclusion: There were no significant difference among the patient 
groups regarding end of treatment and clinical improvement rates, 
speed of recovery and probability of hospital discharge. However, they 
significantly differ in length of hospital stay for RFQs monotherapy.
Keywords: Respiratory quinolones, quinolones, Community-acquired 
pneumonia, length of hospital stay, 30 days mortality, speed of re-
covery.
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Materials and Methods
Study structure and site
A multicenter retrospective study in three hospitals; a 
community service and two teaching hospitals; com-
bined encompass about 750 beds. Data were col-
lected in retrospective manner in between Septem-
ber 2012 - April 2014. Patients were included if they 
were in hospital ward, Mild-to-Moderate severity CAP, 
received oral or parenteral therapy, on RFQs, RFQs in 
combination with ß-lactams, on macrolides/ß-lactams 
combination, on ß-lactam monotherapy, on macro-
lides monotherapy or other antimicrobial agents uti-
lized in CAP, were ≥ 18 years old, who completed ≥ 
3 days of the study antimicrobial and isolated bacteria 
is/are susceptible to at least ≥ 1 antimicrobial agent 
should a culture was available. Patients were excluded 
if they had health care associated pneumonia (HCAP), 
CAP required ICU admission, and CAP treated as an 
out patient, pregnancy, and < 18 years of age and 
lung cancer. Patients were contacted by telephone 30 
days after their hospital discharge. The primary out-
come measures were rates of clinical improvement at 
end of therapy and speed of recovery, secondary out-
come measures were mortality by 30 days and length 
of hospital stay.
CAP Definition 
Patients who suffer of symptoms and signs of CAP 
including cough, fever, chills, rigors, chest pain, 
pleurisy, dyspnea and sputum production (mucopu-
rulent, scant or watery), gastrointestinal symptoms 
including nausea, vomiting, diarrhea, and mental 
status changes, respiratory rate ≥ 24 breaths/min-
ute, tachycardia, audible rales or bronchial sounds. 
Laboratory evaluation: leukocytosis with a left shift 
or leukopenia. The presence of an infiltrate on a 
plain chest radiograph or a chest CT is considered 
the “gold standard” for diagnosing pneumonia 
when clinical and microbiologic features are sup-
portive. Microbiological diagnosis includes an ac-
cepted sputum specimen for Gram’s stain and or 
culture [8], urinary antigen testing, blood culture 
is reliable if positive and establishes the microbial 
diagnosis in the context of diagnosing CAP [4].
Statistical methods
Statistical analysis was set using SPSS version 18 
statistical software. Continuous variables were ana-
lyzed for significant differences by ANOVA, a-sig-
nificance (P-value) is considered significant for dif-
ferences if < 0.05. If significant difference was de-
tected among groups, sensitivity analysis by Tuckey 
HSD test among variables was performed. Pearson 
Chi Square (χ2) was used to detect significant dif-
ferences among comorbidities, laboratory, and ra-
diological diagnoses among different antimicrobial 
therapy groups. Frequencies were used where ap-
propriate for nominal variables. Cumulative curves 
for the probability of hospital discharge were plotted 
for mild CAP (Figure 1); representative curves were 
Figure 1. Cumulative Probability Curve for Hospital Discharge in 
Patients with Mild CAP* in the Therapy Groups
P-values were tested by Kolmogorov-Smirnov test using RFQs as 
the reference curve
RFQs: Respiratory quinolounes. RFQs+: RFQs in combination with 
ß-lactams .OUAT: Other commonly used antimicrobial agents for 
CAP
*The majority of patients were in mild CAP (N = 276; RFQs = 69, 
RFQ+ other agents = 139, OUAT = 68), 43 patients were in medium 
severity group and 1 no PSI available data.
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tested for significant differences for the first seven 
days using RFQs curve as the reference curve for 
the other two curves by Kolmogorov-Smirnov test 
using a web application. Found on http://scistatcalc.
blogspot.com/2013/11/kolmogorov-smirnov-test-
calculator.html. 
Results and Discussion 
A total of 330 patients were included in the study, 
of these 10 were excluded; 1 pregnant, 1 ICU-re-
quiring admission, 2 insufficient data and 6 patients 
for not having the diagnosis of CAP and were not 
treated as such. The mean age for the three antimi-
crobial therapy groups combined was 49.63 years, 
each group age mean has no significant difference 
from the common mean (P = 0.204), the same was 
for gender distribution, males 60.3 % (P = 0.219). 
The three groups had similar patients’ distribution 
as scored by PSI (Pearson X2 test = 13.75, P = 0.185). 
The first group is composed of RFQs (Levofloxacin 
or Moxifloxacin) monotherapy used in 24.4% of 
patients. The second group is composed of a RFQ 
combined with ß-lactams in 50.6% of patients. The 
third group (25%) is composed of the rest; mac-
rolides (Azithromycin or Clarithromycin) combined 
with ß-lactams in 12.2% of patients, ß-lactams 
monotherapy (5.7%), macrolides monotherapy 
2.1%, glycopeptides (11 teicoplanin 3 vancomycin) 
with ß-lactams 4.4% and Doxycycline combined 
with ß-lactams (2 patients) 0.6% (Figure 2).
Comorbidities had no significant distribution dif-
ference among the three groups as shown in (Ta-
ble  3). Diabetes mellitus was the most common 
comorbidity, a total of 84 patients almost evenly 
spread (P = 0.847), followed by kidney disease (17 
patients), bronchial asthma (15 patients), COPD (11 
patients), and immunosuppression (13 patients), 
whereas other comorbidities had no significant dif-
ferences as well (P > 0.05). Radiological diagnosis by 
plain X-rays and CT-scan was universal among pa-
tients. The percentage-yield of the radiological diag-
noses showed no significant difference among the 
three therapy groups for plain X-Rays (P = 0.447) 
and for CT-Scan (P = 0.247). Though modest fre-
quencies of symptoms were obtained from records 
like (Fever, sputum, chest pain, chills/rigors, cough, 
shortness of breath, vomiting and other symptoms), 
yet all groups did not show statistically significant 
differences (Table 1). Sputum culture was minimally 
utilized; it was requested in 39 out of 320 patients 
and a microorganism was identified twice; one 
Streptococcus pneumoniae and the other was Hae-
mophilus influenzae. Blood cultures were ordered 
34 times although febrile patients counted 202 on 
admission; but only one S. aureus was identified.
Rates of clinically improved patients had no signifi-
cant difference among the three therapy groups 
(P = 0.424), as well as speed of recovery (P = 0.398), 
however rates of length of hospital stay was sig-
nificantly shorter for the RFQs monotherapy group 
(P = 0.004), even higher significance was detected 
for mild CAP among the three groups (P < 0.0001). 
Mortality occurred in four patients; 1 patient in the 
Figure 2. Ratios of Antimicrobials Therapy Used to Treat Patients 
with Mild-to-Moderate Community-Acquired Pneumonia
The three therapy groups had no statistical significant PSI score 
difference; Pearson X2 test = 13.75, p = 0.185. 
RFQ: Levofloxacin or Moxifloxacin; Doxy: Doxycycline; Macrolides: 
Azithromycin or Clarithromycin; Glycopeptides: Teicoplanin 
or Vancomycin; ß-lactmas: Aminopeicillins, 3rd Generation 
Cephalosporin or Carbapenems.
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& In combination with ß-lactams, ß-lactams ß-lactamases inhibitors, macrolides, glycopeptides, doxycycline or carbapenems 
(see text).
* Tested by Pearson χ2 test unless stated differently.
@ One way ANOVA, F = 1.599.
OUAT: Other used antimicrobial therapy in CAP, N: number
RFQs: Respiratory fluoroquinolones.
N/A: Not available
# Others comorbidities: Coronary artery diseases, hypertension and one bronchiectasis in the RFQs. No alcoholism, asplenia, 
HIV and endobronchial obstruction were found. 
$ One hematological malignancy and one solid tumor (not lung) in RFQs, no patients were actively treated by immunosup-
pressive therapy at the time of CAP treatment.
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RFQs monotherapy group, and 3 patients in the 
RFQ- ß-lactam combination group (Table 2).
Furthermore, Pearson Chi Square analysis was done 
for clarifying any possible difference in outcome be-
tween mild and moderate CAP for the three thera-
py subgroups, it showed no significant differences 
in rates of clinical improvement among the three 
therapy groups whether mild or moderate CAP (P 
= 0.552), days to recover (P = 0.801 for mild and 
0.557 for moderate severity), death (P > 0.6), length 
of hospital stay showed no significant difference 
for moderate severity CAP (P = 0.717). However 
there was a highly significant difference in length of 
stay among the groups (P < 0.0001) for mild CAP 
in favor of RFQs (Table 2). Cumulative curve for 
the probability of discharge for the first seven days 
was constructed using RFQs probability of discharge 
curve as a reference to compare RFQs-in-combina-
tion and OUAT to; both were not significantly dif-
ferent as tested by Kolmogorov-Smirnov test, they 
were (Maximum deviation D = 0.428571, KS statis-
tic = 0.801784 and p = 0.54) and (D = 0.571429, 
KS statistic = 1.069045, P = 0.20) respectively.
CAP remains a commonly encountered infectious 
disease in clinical practice world-wide; its incidence 
is relatively high in all age groups. In our cohort of 
320 patients study, we focus our attention on the 
most common adult Mild-to-Moderate CAP [1]. Here 
we sought to reveal whether RFQs monotherapy, 
commonly prescribed antimicrobials, differ in out-
come (clinical improvement), speed of recovery and 
length of hospital stay from other regimens. RFQs 
used in this study were Levofloxacin and moxifloxa-
cin, both in monotherapy and in the combination 
groups; Both RFQs were found clinically equivalent 
in Mild-to-Moderate CAP with similar safety pro-
file. A previous study evaluated elderly patients ≥ 
65 years old showed that moxifloxacin superseded 
levofloxacin in speed of recovery (P = 0.01) though 
clinical improvements at end of therapy were similar 
[2, 9, 10].
The end-of- treatment recovery and speed of re-
covery for patients in the RFQs monotherapy versus 
other groups did not differ significantly, implying 
that in age-mixed population with mild-to-moder-
ate CAP, the choice among the recommended an-
Table 2. Rates of Improvement in Patients@ Treated with RFQs monotherapy versus, RFQs in Combination 






Clinically Improved (%) 97.4 93.2 100 0.424
Length of hospital stay (days)** 2.92 3.91 3.77 0.004#
Days to recovery 2.31 2.31 2.08 0.398
Mortality by day 30& 1.0 3.0 0.0 --
OUAT: Other Used Antimicrobial Therapy. PSI: Pneumonia severity score, 
@ Patients number differ for each cell. 
* Significance was tested by ANOVA, F-statistic
** By ANOVA; F = 5.65, Tukey HSD showed significant difference for RFQs versus OUAT (p = 0.044) and versus RFQs in combination (p = 0.003).
# Highly significant difference was found for mild severity CAP (p < 0.0001).
& one in severe PSI class in RFQs group and two in moderate and one in severe PSI class in combination therapy.
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timicrobials is not a major concern if one considers 
appropriate agents and cost effectiveness in the 
treatment of mild-moderate CAP .Nonetheless, the 
three groups did differ significantly in length of hos-
pital stay in favor of RFQs monotherapy (P = 0.004), 
further analysis revealed that the difference became 
highly significant if mild CAP was solely compared 
(P < 0.0001); an interesting point in this study is 
that, if length of hospital stay is shorter, then we 
may conclude that speed of recovery should have 
been faster and patients were discharged sooner. 
Hitherto, this may have an impact on cost savings 
when treating mild CAP that require hospital-ward 
admission [11]. Cumulative probability of daily hospi-
tal discharge in the first week, though was numeri-
cally higher for the RFQs group, it did not reach sta-
tistical difference among the three therapy groups 
(P > 0.05) (Figure 1).
Nonetheless, due to the retrospective nature of the 
study and the use of different treatment protocols, 
one cannot make a firm conclusion. Shorter length 
of stay for the RFQs group monotherapy, especially 
in the mild CAP subset and not in RFQ-combination 
group may be due to the fact that patients were on 
parenteral ß-lactams, and physicians taking care of 
patients may have been delinquent in discontinuing 
parenteral antimicrobials and replacing them with 
oral agents, having uncertainty about the agent 
that caused response in the absence of microbio-
logical diagnosis. RFQs are popular for use among 
clinicians for their simple dosage format, patients’ 
compliance, relatively low adverse effects, and the 
relatively low resistance profile in pneumococcal 
pneumonia despite high utilization [12]. Unfortu-
nately, in the era of new virulent resistance pat-
terns [13], an intense discussions about antimicrobial 
stewardship and prudent use of antimicrobials is on-
going [14, 15], many of practicing physicians have 
used unconventional, complex antimicrobial treat-
ment regimens, including carbapenems and glyco-
peptides in combinations, at times with a macrolide 
or a quinolone. We can only hope that this study 
will convince physicians that simple recommended 
regimens in the treatment of Mild-to-Moderate 
CAP is as good as complicated unnecessary ones, 
with less patients’ adverse effects [16], and promot-
ing less resistance [17].
An added concern is that in real life, practicing phy-
sicians were not keen to obtain sputum for analysis 
and culture as well as blood cultures, though 32.8% 
of patients produced sputum and 63.1% had fe-
ver, unfortunately this attitude has been increasing 
worldwide over years [18,19], though all patients 
needed hospital admission for more aggressive 
management.
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